NOVELTY NOBILITY Inc.

Learn More

Details: Fully human IgG1 monoclonal antibody discovered by Novelty Nobility

Science: Unlike most investigational retinal therapies which are currently participating in a race to increase the durability of anti-VEGF therapies, we focus on the fundamentals of the retinal diseases — hypoxia. Hypoxia-inducible factor-1α (HIF-1α) is a transcription factor stabilized by hypoxia, playing a pivotal role in the onset and development of retinal diseases. Interestingly, our c-Kit inhibitor NN2101 regulates HIF-1α and mediates vascular permeability, inducing vessel normalization and resolution of hypoxia. We dream of curing retinal diseases.

Publications

Learn More

Details: Fully human IgG1 monoclonal antibody discovered by Novelty Nobility

Science: c-Kit is expressed in various cells, including mast cells, which mediate inflammatory responses such as hypersensitivity and allergic reactions. SCF/c-Kit signaling controls the differentiation, tissue recruitment, survival and activity of mast cells. In inflammatory diseases, such as chronic urticaria, mast cell activation plays a central role in the onset and progression of the disease. Our anti-c-Kit antibody specifically binds c-Kit with high specificity and potently inhibits its activity.

Publications: 1. [Mol. Cell. Biochem] A fully human anti‑c‑Kit monoclonal antibody 2G4 inhibits proliferation and degranulation of human mast cells (2022)

Learn More

Details: Novel antibody-drug conjugate (ADC) designed and created by Novelty Nobility- Fully human IgG1 monoclonal antibody discovered by Novelty Nobility conjugated with ThioBridge®, a proprietary site-specific ADC cleavable linker technology of Abzena, and MMAE with DAR 4

Science: Developed to treat both c-Kit wildtype and activating mutation-driven cancers, NN3201 monotherapy exhibited complete remission in all tested xenograft model studies of hard-to-treat cancers such as SCLC and AML. This novel ADC is powered by dual modalities that simultaneously address the tumor microenvironment (TME) via c-Kit pathway inhibition and by targeting c-Kit positive tumors for ADC internalization. NN3201 also demonstrates a superior preclinical safety profile with a large therapeutic index.

Publications

Learn More

Science: An undruggable target from a traditional antibody perspective, RAS mutations regulate induction of a certain membrane protein, our undisclosed target. Pan RAS mutations and overexpression of our undisclosed target are found to be highly correlated in various RAS-driven tumors. As such, NN3206 is designed to demonstrate superb RAS subtype- or mutation-agnostic pharmacological activities.